Peter Corry
Concepts (422)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperthermia, Induced | 24 | 2012 | 115 | 2.020 |
Why?
| Heat-Shock Proteins | 11 | 2005 | 100 | 1.280 |
Why?
| Radiotherapy, Intensity-Modulated | 10 | 2017 | 177 | 1.160 |
Why?
| Hot Temperature | 27 | 2012 | 198 | 1.060 |
Why?
| Radiotherapy Planning, Computer-Assisted | 12 | 2017 | 253 | 1.000 |
Why?
| Antioxidants | 2 | 2020 | 239 | 0.900 |
Why?
| Radiometry | 8 | 2017 | 123 | 0.840 |
Why?
| Neoplasms | 19 | 2016 | 1251 | 0.790 |
Why?
| Tomography, Spiral Computed | 5 | 2017 | 56 | 0.720 |
Why?
| Radiation-Protective Agents | 3 | 2020 | 72 | 0.710 |
Why?
| Abdomen | 2 | 2011 | 75 | 0.700 |
Why?
| Gene Expression Regulation, Neoplastic | 12 | 2012 | 833 | 0.650 |
Why?
| Heart | 4 | 2013 | 341 | 0.620 |
Why?
| Radiotherapy | 4 | 2014 | 125 | 0.610 |
Why?
| Oxygen | 3 | 2012 | 321 | 0.610 |
Why?
| Radiotherapy, Image-Guided | 3 | 2016 | 23 | 0.570 |
Why?
| Pneumonia, Viral | 1 | 2020 | 169 | 0.550 |
Why?
| Radiation Injuries, Experimental | 6 | 2013 | 80 | 0.550 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.540 |
Why?
| Organ Sparing Treatments | 3 | 2016 | 56 | 0.530 |
Why?
| Pandemics | 1 | 2020 | 563 | 0.490 |
Why?
| Mammary Neoplasms, Experimental | 3 | 2012 | 121 | 0.480 |
Why?
| Radiosurgery | 2 | 2016 | 123 | 0.460 |
Why?
| Animals | 47 | 2021 | 13124 | 0.460 |
Why?
| Cell Survival | 22 | 2012 | 589 | 0.450 |
Why?
| Organs at Risk | 3 | 2016 | 71 | 0.440 |
Why?
| Head and Neck Neoplasms | 3 | 2017 | 287 | 0.430 |
Why?
| Tumor Cells, Cultured | 22 | 2001 | 457 | 0.420 |
Why?
| Radiotherapy Dosage | 13 | 2017 | 248 | 0.420 |
Why?
| Peptides | 3 | 2012 | 221 | 0.410 |
Why?
| HSP70 Heat-Shock Proteins | 5 | 1995 | 60 | 0.410 |
Why?
| Radiation Injuries | 3 | 2013 | 112 | 0.410 |
Why?
| Isoquinolines | 5 | 1996 | 25 | 0.400 |
Why?
| Ultrasonic Therapy | 5 | 2008 | 34 | 0.400 |
Why?
| Galectin 1 | 1 | 2012 | 20 | 0.390 |
Why?
| Blood Vessels | 1 | 2012 | 71 | 0.380 |
Why?
| Protein Kinase C | 7 | 1996 | 71 | 0.370 |
Why?
| Molecular Targeted Therapy | 1 | 2012 | 123 | 0.370 |
Why?
| Piperazines | 5 | 1996 | 119 | 0.370 |
Why?
| Brain Neoplasms | 2 | 2012 | 291 | 0.370 |
Why?
| Bone and Bones | 2 | 2011 | 478 | 0.350 |
Why?
| Prostatic Neoplasms | 6 | 2017 | 384 | 0.350 |
Why?
| Myocardium | 4 | 2014 | 445 | 0.350 |
Why?
| Acetylcysteine | 2 | 2010 | 101 | 0.340 |
Why?
| Carcinoma, Squamous Cell | 2 | 2012 | 326 | 0.340 |
Why?
| Fibroblast Growth Factor 2 | 4 | 1999 | 34 | 0.340 |
Why?
| Sulfonamides | 3 | 1995 | 126 | 0.330 |
Why?
| Mice | 13 | 2021 | 5687 | 0.320 |
Why?
| Bone Density | 1 | 2011 | 386 | 0.320 |
Why?
| Image Processing, Computer-Assisted | 3 | 2017 | 243 | 0.320 |
Why?
| Cranial Irradiation | 2 | 2009 | 20 | 0.320 |
Why?
| Cerebellar Neoplasms | 2 | 2009 | 23 | 0.320 |
Why?
| Combined Modality Therapy | 10 | 2012 | 641 | 0.310 |
Why?
| Heat-Shock Response | 2 | 2005 | 26 | 0.300 |
Why?
| Medulloblastoma | 1 | 2008 | 17 | 0.300 |
Why?
| Oxygen Consumption | 1 | 2009 | 190 | 0.290 |
Why?
| Humans | 59 | 2021 | 50503 | 0.290 |
Why?
| Sodium Compounds | 4 | 1994 | 11 | 0.280 |
Why?
| Arsenites | 4 | 1994 | 13 | 0.280 |
Why?
| Arsenic | 3 | 1991 | 22 | 0.270 |
Why?
| Whole-Body Irradiation | 3 | 2020 | 132 | 0.270 |
Why?
| Cell Hypoxia | 2 | 2012 | 82 | 0.260 |
Why?
| Radiobiology | 1 | 2005 | 21 | 0.250 |
Why?
| Breast Neoplasms | 9 | 2016 | 1201 | 0.250 |
Why?
| Medicine | 1 | 2005 | 56 | 0.240 |
Why?
| Radiation Dosage | 7 | 2008 | 162 | 0.240 |
Why?
| Dose-Response Relationship, Radiation | 8 | 2012 | 183 | 0.240 |
Why?
| Rats | 17 | 2021 | 3292 | 0.240 |
Why?
| Brain | 1 | 2012 | 1319 | 0.220 |
Why?
| Quercetin | 2 | 1994 | 15 | 0.220 |
Why?
| Brachytherapy | 7 | 1998 | 46 | 0.210 |
Why?
| Signal Transduction | 5 | 2013 | 1624 | 0.210 |
Why?
| Promoter Regions, Genetic | 4 | 2001 | 465 | 0.210 |
Why?
| Tocotrienols | 2 | 2013 | 37 | 0.210 |
Why?
| Radiotherapy, Conformal | 2 | 2016 | 53 | 0.210 |
Why?
| Radiation Tolerance | 7 | 2013 | 84 | 0.210 |
Why?
| Neovascularization, Pathologic | 3 | 2012 | 155 | 0.200 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2000 | 155 | 0.200 |
Why?
| Paclitaxel | 2 | 2009 | 84 | 0.200 |
Why?
| Transcription Factor AP-1 | 3 | 1999 | 62 | 0.200 |
Why?
| Glucose | 4 | 2000 | 341 | 0.190 |
Why?
| Cell Line | 12 | 2005 | 988 | 0.190 |
Why?
| Gene Expression | 5 | 2012 | 610 | 0.190 |
Why?
| Drug Resistance, Multiple | 6 | 2000 | 24 | 0.190 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.190 |
Why?
| Cricetinae | 14 | 2021 | 188 | 0.190 |
Why?
| Cell Nucleus | 4 | 1991 | 182 | 0.180 |
Why?
| Cycloheximide | 6 | 1994 | 35 | 0.180 |
Why?
| Lung Neoplasms | 3 | 2017 | 601 | 0.180 |
Why?
| Angiogenesis Inhibitors | 2 | 2012 | 183 | 0.170 |
Why?
| Models, Biological | 3 | 2016 | 716 | 0.170 |
Why?
| Crystallins | 2 | 1996 | 11 | 0.160 |
Why?
| Carcinoma | 4 | 1999 | 137 | 0.160 |
Why?
| Temperature | 7 | 2005 | 162 | 0.150 |
Why?
| Male | 21 | 2021 | 25907 | 0.150 |
Why?
| MicroRNAs | 1 | 2021 | 344 | 0.140 |
Why?
| Tomography, X-Ray Computed | 4 | 2016 | 1164 | 0.140 |
Why?
| Colonic Neoplasms | 8 | 1995 | 158 | 0.140 |
Why?
| Enzyme Inhibitors | 3 | 1996 | 377 | 0.140 |
Why?
| Genes, bcl-2 | 1 | 1997 | 5 | 0.140 |
Why?
| Radiation-Sensitizing Agents | 2 | 2010 | 51 | 0.140 |
Why?
| Rectum | 4 | 1998 | 52 | 0.140 |
Why?
| Genes, myc | 1 | 1997 | 32 | 0.140 |
Why?
| RNA, Messenger | 7 | 1999 | 1089 | 0.140 |
Why?
| Esophageal Neoplasms | 1 | 1998 | 106 | 0.130 |
Why?
| Calcitriol | 1 | 1996 | 39 | 0.130 |
Why?
| Kinetics | 7 | 1996 | 623 | 0.130 |
Why?
| Base Sequence | 7 | 1996 | 639 | 0.130 |
Why?
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 5 | 1996 | 7 | 0.130 |
Why?
| Time Factors | 10 | 2014 | 2935 | 0.130 |
Why?
| Radiation Protection | 2 | 2016 | 47 | 0.130 |
Why?
| Molecular Sequence Data | 7 | 1996 | 778 | 0.130 |
Why?
| Cell Line, Tumor | 4 | 2012 | 1398 | 0.130 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 1808 | 0.120 |
Why?
| Fourier Analysis | 1 | 1995 | 18 | 0.120 |
Why?
| DNA-Binding Proteins | 3 | 1994 | 418 | 0.120 |
Why?
| Craniospinal Irradiation | 1 | 2014 | 9 | 0.120 |
Why?
| Radiation Pneumonitis | 2 | 2016 | 9 | 0.110 |
Why?
| Equipment Design | 2 | 2012 | 289 | 0.110 |
Why?
| Harringtonines | 1 | 1993 | 3 | 0.110 |
Why?
| Apoptosis | 2 | 2014 | 1097 | 0.110 |
Why?
| Membrane Proteins | 1 | 1996 | 332 | 0.110 |
Why?
| Phantoms, Imaging | 3 | 2011 | 122 | 0.110 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 154 | 0.110 |
Why?
| Pentoxifylline | 1 | 2013 | 14 | 0.110 |
Why?
| Immunohistochemistry | 2 | 2013 | 957 | 0.110 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 1993 | 66 | 0.110 |
Why?
| Transcription Factors | 2 | 1994 | 565 | 0.110 |
Why?
| Phosphorylation | 4 | 2013 | 525 | 0.110 |
Why?
| Monte Carlo Method | 1 | 2013 | 85 | 0.110 |
Why?
| Oxidative Stress | 4 | 2012 | 772 | 0.100 |
Why?
| Female | 25 | 2021 | 27081 | 0.100 |
Why?
| Kininogens | 1 | 2012 | 3 | 0.100 |
Why?
| Kallikrein-Kinin System | 1 | 2012 | 3 | 0.100 |
Why?
| Ablation Techniques | 1 | 2012 | 22 | 0.100 |
Why?
| Deuterium | 1 | 1992 | 45 | 0.100 |
Why?
| Tumor Burden | 2 | 2010 | 130 | 0.100 |
Why?
| Cisplatin | 4 | 2009 | 286 | 0.100 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2011 | 181 | 0.100 |
Why?
| Computer Simulation | 5 | 2016 | 279 | 0.100 |
Why?
| Bystander Effect | 1 | 2012 | 25 | 0.100 |
Why?
| Carrier Proteins | 1 | 1993 | 298 | 0.100 |
Why?
| Mitogen-Activated Protein Kinase 1 | 4 | 2013 | 50 | 0.100 |
Why?
| Oligodeoxyribonucleotides | 4 | 1996 | 33 | 0.100 |
Why?
| Adaptation, Physiological | 1 | 1992 | 93 | 0.100 |
Why?
| Models, Chemical | 2 | 2008 | 64 | 0.100 |
Why?
| Myocarditis | 1 | 2012 | 46 | 0.100 |
Why?
| Adenoviridae | 3 | 2001 | 48 | 0.100 |
Why?
| Acclimatization | 1 | 1991 | 17 | 0.100 |
Why?
| Models, Theoretical | 1 | 2012 | 170 | 0.090 |
Why?
| Organ Specificity | 1 | 2011 | 109 | 0.090 |
Why?
| Genetic Vectors | 3 | 2001 | 128 | 0.090 |
Why?
| Transcription, Genetic | 3 | 1999 | 361 | 0.090 |
Why?
| Cell Proliferation | 2 | 2012 | 985 | 0.090 |
Why?
| Nuclear Proteins | 1 | 1992 | 238 | 0.090 |
Why?
| Neoplasm Proteins | 1 | 1993 | 320 | 0.090 |
Why?
| Transfection | 4 | 2000 | 356 | 0.090 |
Why?
| Mitochondria | 1 | 2014 | 399 | 0.090 |
Why?
| Leukocyte Count | 1 | 2010 | 69 | 0.090 |
Why?
| Radiography | 2 | 2009 | 485 | 0.090 |
Why?
| CHO Cells | 5 | 1992 | 118 | 0.090 |
Why?
| Cytokines | 1 | 1993 | 606 | 0.080 |
Why?
| Drug Resistance, Neoplasm | 3 | 1997 | 316 | 0.080 |
Why?
| Genes, jun | 3 | 1999 | 21 | 0.080 |
Why?
| Middle Aged | 9 | 2021 | 12611 | 0.080 |
Why?
| Genes, fos | 3 | 1999 | 28 | 0.080 |
Why?
| Taxoids | 1 | 2009 | 37 | 0.080 |
Why?
| Carboplatin | 1 | 2009 | 54 | 0.080 |
Why?
| Fluorouracil | 1 | 2009 | 58 | 0.080 |
Why?
| Body Weight | 1 | 2011 | 517 | 0.080 |
Why?
| Disease Progression | 1 | 2012 | 829 | 0.080 |
Why?
| Information Systems | 1 | 1989 | 27 | 0.080 |
Why?
| Nucleoside Deaminases | 2 | 1999 | 3 | 0.080 |
Why?
| Spinal Neoplasms | 1 | 2009 | 30 | 0.080 |
Why?
| Cell Death | 3 | 2005 | 175 | 0.080 |
Why?
| Necrosis | 1 | 2009 | 174 | 0.080 |
Why?
| Follow-Up Studies | 3 | 2009 | 2242 | 0.080 |
Why?
| Thymidine Kinase | 2 | 1999 | 18 | 0.080 |
Why?
| Aged | 6 | 2021 | 9741 | 0.080 |
Why?
| History, 20th Century | 1 | 2009 | 100 | 0.080 |
Why?
| Microscopy, Fluorescence | 1 | 2009 | 158 | 0.080 |
Why?
| Osteogenesis | 1 | 2011 | 356 | 0.080 |
Why?
| Bone Marrow | 2 | 2010 | 363 | 0.080 |
Why?
| Gene Expression Regulation | 3 | 2021 | 955 | 0.080 |
Why?
| Carbon | 1 | 2008 | 55 | 0.080 |
Why?
| Reactive Oxygen Species | 1 | 2010 | 409 | 0.070 |
Why?
| Protein Biosynthesis | 1 | 1990 | 232 | 0.070 |
Why?
| Weight Loss | 1 | 2010 | 245 | 0.070 |
Why?
| Genetic Therapy | 2 | 1999 | 120 | 0.070 |
Why?
| Radiotherapy, Computer-Assisted | 1 | 2007 | 16 | 0.070 |
Why?
| Skull | 1 | 2007 | 75 | 0.070 |
Why?
| Adult | 8 | 2021 | 13577 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 4 | 1995 | 1372 | 0.070 |
Why?
| Spine | 1 | 2007 | 90 | 0.070 |
Why?
| Ovary | 6 | 1990 | 103 | 0.070 |
Why?
| Central Nervous System Neoplasms | 1 | 2007 | 63 | 0.070 |
Why?
| 3T3 Cells | 3 | 1996 | 56 | 0.070 |
Why?
| Particle Accelerators | 2 | 2017 | 51 | 0.070 |
Why?
| Antineoplastic Agents | 2 | 1993 | 1172 | 0.060 |
Why?
| Swine | 3 | 2012 | 408 | 0.060 |
Why?
| DNA Damage | 4 | 2012 | 301 | 0.060 |
Why?
| Blotting, Northern | 3 | 1996 | 110 | 0.060 |
Why?
| Rats, Sprague-Dawley | 3 | 2014 | 1585 | 0.060 |
Why?
| DNA Repair | 4 | 1988 | 188 | 0.060 |
Why?
| DNA, Neoplasm | 2 | 1993 | 143 | 0.060 |
Why?
| Antiviral Agents | 3 | 2021 | 170 | 0.060 |
Why?
| Retrospective Studies | 3 | 2012 | 6263 | 0.060 |
Why?
| Aged, 80 and over | 3 | 2021 | 3226 | 0.060 |
Why?
| Treatment Outcome | 2 | 2012 | 5283 | 0.060 |
Why?
| Cytomegalovirus | 2 | 2001 | 28 | 0.060 |
Why?
| Hydrogen-Ion Concentration | 3 | 1994 | 168 | 0.060 |
Why?
| Diathermy | 1 | 1983 | 1 | 0.050 |
Why?
| Recombinant Proteins | 3 | 2000 | 476 | 0.050 |
Why?
| Cricetulus | 8 | 1990 | 97 | 0.050 |
Why?
| Magnetics | 1 | 1983 | 35 | 0.050 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1000 | 0.050 |
Why?
| X-Rays | 4 | 2016 | 55 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 49 | 0.050 |
Why?
| JNK Mitogen-Activated Protein Kinases | 2 | 2000 | 71 | 0.050 |
Why?
| Antigens, Differentiation, Myelomonocytic | 2 | 2013 | 39 | 0.050 |
Why?
| Genes, Recessive | 1 | 2002 | 15 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2002 | 17 | 0.050 |
Why?
| Flucytosine | 2 | 1999 | 13 | 0.050 |
Why?
| Antimetabolites | 2 | 1999 | 12 | 0.050 |
Why?
| Ganciclovir | 2 | 1999 | 25 | 0.050 |
Why?
| Genetic Markers | 1 | 2002 | 104 | 0.050 |
Why?
| Sensitivity and Specificity | 3 | 2009 | 859 | 0.050 |
Why?
| Microcephaly | 1 | 2002 | 41 | 0.050 |
Why?
| Ultrasonics | 1 | 1982 | 30 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Antigens, CD | 2 | 2013 | 222 | 0.050 |
Why?
| Leucine | 2 | 1994 | 117 | 0.050 |
Why?
| Genetic Variation | 1 | 2002 | 207 | 0.050 |
Why?
| Glycolysis | 1 | 2021 | 69 | 0.050 |
Why?
| Transgenes | 1 | 2001 | 52 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 226 | 0.050 |
Why?
| Genes, Reporter | 1 | 2001 | 88 | 0.040 |
Why?
| Luminescent Proteins | 1 | 2001 | 53 | 0.040 |
Why?
| Recombinant Fusion Proteins | 2 | 1999 | 179 | 0.040 |
Why?
| Green Fluorescent Proteins | 1 | 2001 | 90 | 0.040 |
Why?
| Algorithms | 2 | 2016 | 625 | 0.040 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 61 | 0.040 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 1999 | 77 | 0.040 |
Why?
| Prodrugs | 1 | 1999 | 31 | 0.040 |
Why?
| Rabbits | 2 | 2010 | 372 | 0.040 |
Why?
| Linear Models | 2 | 2016 | 279 | 0.040 |
Why?
| Proteomics | 1 | 2021 | 314 | 0.040 |
Why?
| Clinical Trials as Topic | 2 | 1991 | 486 | 0.040 |
Why?
| Blotting, Western | 3 | 2012 | 578 | 0.040 |
Why?
| Reproducibility of Results | 3 | 2009 | 1197 | 0.040 |
Why?
| Protein Kinase C-alpha | 2 | 2013 | 10 | 0.040 |
Why?
| Rectal Diseases | 1 | 1997 | 10 | 0.040 |
Why?
| Proteins | 2 | 2010 | 339 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 610 | 0.030 |
Why?
| Protein Binding | 2 | 1996 | 654 | 0.030 |
Why?
| Cell Division | 2 | 1996 | 291 | 0.030 |
Why?
| Glioma | 3 | 1993 | 77 | 0.030 |
Why?
| Body Temperature | 2 | 1989 | 67 | 0.030 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 32 | 0.030 |
Why?
| Wound Healing | 1 | 1998 | 186 | 0.030 |
Why?
| Cell Cycle | 2 | 1995 | 226 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 179 | 0.030 |
Why?
| HSP30 Heat-Shock Proteins | 1 | 1996 | 1 | 0.030 |
Why?
| DNA | 4 | 1988 | 535 | 0.030 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1996 | 47 | 0.030 |
Why?
| Receptors, Calcitriol | 1 | 1996 | 22 | 0.030 |
Why?
| Leukemia, Myeloid | 1 | 1996 | 44 | 0.030 |
Why?
| Isoenzymes | 1 | 1996 | 168 | 0.030 |
Why?
| Cone-Beam Computed Tomography | 1 | 2016 | 33 | 0.030 |
Why?
| Poisson Distribution | 1 | 2016 | 33 | 0.030 |
Why?
| Electrophoresis, Polyacrylamide Gel | 2 | 1996 | 98 | 0.030 |
Why?
| Quality Assurance, Health Care | 3 | 1991 | 150 | 0.030 |
Why?
| Flow Cytometry | 2 | 1996 | 474 | 0.030 |
Why?
| Probability | 1 | 2016 | 164 | 0.030 |
Why?
| Adolescent | 4 | 2009 | 6443 | 0.030 |
Why?
| Hypoglycemia | 1 | 1996 | 55 | 0.030 |
Why?
| G2 Phase | 1 | 1995 | 13 | 0.030 |
Why?
| Multiple Myeloma | 1 | 2010 | 2998 | 0.030 |
Why?
| Fibrosarcoma | 2 | 2011 | 12 | 0.030 |
Why?
| Radio Waves | 1 | 1995 | 7 | 0.030 |
Why?
| Neoplasms, Experimental | 2 | 2009 | 110 | 0.030 |
Why?
| Thermodynamics | 1 | 1995 | 33 | 0.030 |
Why?
| Mathematics | 1 | 1995 | 44 | 0.030 |
Why?
| Radiation, Ionizing | 1 | 1995 | 100 | 0.030 |
Why?
| Mitosis | 1 | 1995 | 88 | 0.030 |
Why?
| Dimethyl Sulfoxide | 1 | 1994 | 13 | 0.030 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 18 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 36 | 0.030 |
Why?
| Gliosarcoma | 1 | 1994 | 5 | 0.030 |
Why?
| Cell Respiration | 1 | 2014 | 41 | 0.030 |
Why?
| HSC70 Heat-Shock Proteins | 1 | 1993 | 7 | 0.030 |
Why?
| Enzyme Activation | 3 | 2000 | 268 | 0.030 |
Why?
| bcl-2-Associated X Protein | 1 | 2014 | 57 | 0.030 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 1994 | 51 | 0.030 |
Why?
| Child, Preschool | 3 | 2009 | 3942 | 0.030 |
Why?
| Protein Conformation | 1 | 2014 | 162 | 0.030 |
Why?
| Software | 1 | 2016 | 276 | 0.030 |
Why?
| Cell Count | 1 | 2013 | 150 | 0.030 |
Why?
| Mast Cells | 1 | 2013 | 54 | 0.030 |
Why?
| Cells, Cultured | 4 | 1991 | 1571 | 0.030 |
Why?
| Cell Differentiation | 1 | 1996 | 640 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 128 | 0.030 |
Why?
| Drug Interactions | 1 | 2013 | 206 | 0.030 |
Why?
| Skin Temperature | 1 | 2012 | 15 | 0.030 |
Why?
| Multigene Family | 1 | 1992 | 54 | 0.030 |
Why?
| Mitochondrial Swelling | 1 | 2012 | 4 | 0.030 |
Why?
| Rats, Inbred BN | 1 | 2012 | 13 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 156 | 0.030 |
Why?
| Receptor, Bradykinin B2 | 1 | 2012 | 7 | 0.030 |
Why?
| Models, Animal | 1 | 2013 | 227 | 0.030 |
Why?
| DNA Probes | 1 | 1992 | 29 | 0.030 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.020 |
Why?
| Up-Regulation | 1 | 2014 | 446 | 0.020 |
Why?
| Administration, Oral | 1 | 2013 | 434 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2012 | 117 | 0.020 |
Why?
| Cell Fractionation | 1 | 1991 | 11 | 0.020 |
Why?
| Neck | 1 | 2012 | 99 | 0.020 |
Why?
| Burns | 2 | 2012 | 165 | 0.020 |
Why?
| Endothelial Cells | 1 | 2013 | 258 | 0.020 |
Why?
| Computer-Aided Design | 1 | 2011 | 22 | 0.020 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 45 | 0.020 |
Why?
| Evaluation Studies as Topic | 2 | 1988 | 107 | 0.020 |
Why?
| Partial Pressure | 1 | 2011 | 14 | 0.020 |
Why?
| Heart Ventricles | 1 | 2013 | 265 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 572 | 0.020 |
Why?
| Protein Synthesis Inhibitors | 1 | 1990 | 17 | 0.020 |
Why?
| Bone Transplantation | 1 | 2010 | 45 | 0.020 |
Why?
| Child | 3 | 2009 | 6906 | 0.020 |
Why?
| Cell Transformation, Neoplastic | 1 | 2011 | 181 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 181 | 0.020 |
Why?
| Feasibility Studies | 1 | 2011 | 390 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 68 | 0.020 |
Why?
| Filing | 1 | 1989 | 1 | 0.020 |
Why?
| DNA, Single-Stranded | 3 | 1979 | 89 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Cytosine Deaminase | 2 | 1999 | 7 | 0.020 |
Why?
| Metaphase | 1 | 1968 | 45 | 0.020 |
Why?
| Chromosomes | 1 | 1968 | 31 | 0.020 |
Why?
| Metals | 1 | 2008 | 35 | 0.020 |
Why?
| Acute Disease | 1 | 2009 | 373 | 0.020 |
Why?
| Glutathione | 2 | 2000 | 299 | 0.020 |
Why?
| Lung | 1 | 2011 | 504 | 0.020 |
Why?
| Survival Rate | 1 | 2009 | 909 | 0.020 |
Why?
| Skin | 1 | 2009 | 388 | 0.020 |
Why?
| Kidney | 1 | 2011 | 696 | 0.020 |
Why?
| Rats, Wistar | 2 | 1997 | 224 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 978 | 0.020 |
Why?
| Liver | 1 | 2011 | 1132 | 0.020 |
Why?
| Electrodes | 1 | 1984 | 35 | 0.010 |
Why?
| Consanguinity | 1 | 2002 | 17 | 0.010 |
Why?
| Microsatellite Repeats | 1 | 2002 | 37 | 0.010 |
Why?
| Medical Laboratory Science | 1 | 1982 | 2 | 0.010 |
Why?
| Cystamine | 1 | 1982 | 2 | 0.010 |
Why?
| Cysteamine | 1 | 1982 | 7 | 0.010 |
Why?
| Gases | 1 | 1982 | 9 | 0.010 |
Why?
| Methods | 1 | 1981 | 55 | 0.010 |
Why?
| Thoracic Neoplasms | 1 | 1981 | 13 | 0.010 |
Why?
| Abdominal Neoplasms | 1 | 1981 | 15 | 0.010 |
Why?
| Pelvic Neoplasms | 1 | 1981 | 14 | 0.010 |
Why?
| Cell Adhesion | 1 | 1982 | 157 | 0.010 |
Why?
| Intellectual Disability | 1 | 2002 | 127 | 0.010 |
Why?
| Cytarabine | 1 | 1981 | 37 | 0.010 |
Why?
| Clinical Protocols | 2 | 1991 | 110 | 0.010 |
Why?
| Mitomycins | 1 | 1980 | 2 | 0.010 |
Why?
| Dipeptides | 1 | 2000 | 22 | 0.010 |
Why?
| Cysteine | 1 | 2000 | 50 | 0.010 |
Why?
| Phenotype | 1 | 2002 | 739 | 0.010 |
Why?
| Bleomycin | 1 | 1979 | 34 | 0.010 |
Why?
| Young Adult | 1 | 2009 | 4102 | 0.010 |
Why?
| Antimetabolites, Antineoplastic | 1 | 1999 | 35 | 0.010 |
Why?
| Gene Expression Regulation, Viral | 1 | 1999 | 47 | 0.010 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 1999 | 50 | 0.010 |
Why?
| Herpesvirus 1, Human | 1 | 1998 | 15 | 0.010 |
Why?
| Doxorubicin | 1 | 2000 | 236 | 0.010 |
Why?
| Glutathione Disulfide | 1 | 1998 | 40 | 0.010 |
Why?
| Gene Transfer Techniques | 1 | 1998 | 41 | 0.010 |
Why?
| Iridium Radioisotopes | 1 | 1997 | 3 | 0.010 |
Why?
| Glutamic Acid | 1 | 1998 | 113 | 0.010 |
Why?
| S Phase | 1 | 1996 | 18 | 0.010 |
Why?
| Escherichia coli | 1 | 1998 | 190 | 0.010 |
Why?
| Glutamine | 1 | 1998 | 175 | 0.010 |
Why?
| DNA, Complementary | 1 | 1996 | 133 | 0.010 |
Why?
| Cytoplasm | 1 | 1996 | 89 | 0.010 |
Why?
| Adenocarcinoma | 1 | 1980 | 397 | 0.010 |
Why?
| Intestinal Obstruction | 1 | 1996 | 36 | 0.010 |
Why?
| Diarrhea | 1 | 1996 | 90 | 0.010 |
Why?
| Plasmids | 1 | 1996 | 164 | 0.010 |
Why?
| Infant, Newborn | 1 | 2002 | 2749 | 0.010 |
Why?
| Sodium Salicylate | 1 | 1994 | 4 | 0.010 |
Why?
| Cadmium Chloride | 1 | 1994 | 3 | 0.010 |
Why?
| Stimulation, Chemical | 1 | 1994 | 30 | 0.010 |
Why?
| Physical Stimulation | 1 | 1994 | 35 | 0.010 |
Why?
| Electrons | 1 | 1974 | 19 | 0.010 |
Why?
| Adaptation, Biological | 1 | 1994 | 10 | 0.010 |
Why?
| Cadmium | 1 | 1994 | 21 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1994 | 40 | 0.010 |
Why?
| Chlorides | 1 | 1994 | 49 | 0.010 |
Why?
| Infant | 1 | 2002 | 3628 | 0.010 |
Why?
| Stress, Physiological | 1 | 1994 | 171 | 0.010 |
Why?
| Disease Models, Animal | 1 | 1997 | 1436 | 0.010 |
Why?
| Equipment Safety | 1 | 1991 | 12 | 0.010 |
Why?
| Fibroblasts | 1 | 1993 | 336 | 0.010 |
Why?
| Documentation | 1 | 1991 | 33 | 0.010 |
Why?
| Histidinol | 1 | 1990 | 1 | 0.010 |
Why?
| Puromycin | 1 | 1990 | 3 | 0.010 |
Why?
| Electromagnetic Phenomena | 1 | 1988 | 4 | 0.000 |
Why?
| Drug Synergism | 1 | 1981 | 151 | 0.000 |
Why?
| Cross-Linking Reagents | 1 | 1980 | 41 | 0.000 |
Why?
| Remission, Spontaneous | 1 | 1979 | 24 | 0.000 |
Why?
| Creatine Kinase | 1 | 1979 | 29 | 0.000 |
Why?
| L-Lactate Dehydrogenase | 1 | 1979 | 60 | 0.000 |
Why?
| Tachycardia | 1 | 1979 | 28 | 0.000 |
Why?
| Etoposide | 1 | 1979 | 77 | 0.000 |
Why?
| Drug Therapy, Combination | 1 | 1980 | 384 | 0.000 |
Why?
| Peripheral Nervous System Diseases | 1 | 1979 | 58 | 0.000 |
Why?
| Neoplasm Metastasis | 1 | 1979 | 232 | 0.000 |
Why?
| Melphalan | 1 | 1979 | 178 | 0.000 |
Why?
| Electroencephalography | 1 | 1979 | 304 | 0.000 |
Why?
| Melanoma | 1 | 1979 | 280 | 0.000 |
Why?
| Relative Biological Effectiveness | 1 | 1974 | 8 | 0.000 |
Why?
| Centrifugation, Density Gradient | 1 | 1974 | 18 | 0.000 |
Why?
| Gamma Rays | 1 | 1974 | 47 | 0.000 |
Why?
|
|
Corry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|